



Elwyn Cabebe

 Curriculum Vitae available Online

CLINICAL OFFICE (PRIMARY)

2589 Samaritan Dr

San Jose, CA 95124

Tel (408) 426-4900 Fax (669) 233-2061

ACADEMIC CONTACT INFORMATION

• Administrative Contact

Tel 408-426-4900

Professional Overview

BIO

Dr. Elwyn Cabebe is a general medical oncologist and hematologist. He is the Director of Oncology Quality for the Stanford University HealthCare Alliance. He specializes and is board certified in oncology, hematology, internal medicine, and hospice and palliative care.

As a community leader in general oncology and hematology with over 10 years in private practice, Dr. Cabebe is inspired by his patients' continuous rise to the challenge of fighting illness and the constant re-defining of "normal." He strives to provide truthful and compassionate care as well as developing a partnership of shared decision making with his patients.

He recognizes that cancer is an uninvited, life altering condition. He feels that his role for patients and their families is to shepherd them through the difficult process of a cancer diagnosis and treatment with the focus on maintaining the best quality of life possible.

Prior to medical school, Dr. Cabebe was a research associate at Genentech, Inc., helping to develop many of the modern cancer drugs used today.

During his fellowship at Stanford Medicine, Dr. Cabebe served as clinical instructor and conducted various phase clinical trials in solid tumors with emphasis in gastrointestinal malignancies, pancreatic and colorectal cancers, as well as early phase I trials with the Experimental Therapeutics Program. He also served as Adjunct Clinical Faculty after fellowship.

Dr. Cabebe holds various medical directorship roles including Medical Director of Oncology and Chair of the Cancer Committee at Good Samaritan Hospital in Los Gatos, California. He was also the past Medical Director for Clinical Research at El Camino Hospital in Mountain View, California. Dr. Cabebe serves as Expert Medical Reviewer for the California Medical Board as well as author for various cancer reviews on WebMD and Medscape.

CLINICAL FOCUS

- Medical Oncology
- Clinical Trials
- Gastrointestinal Malignancy

- Cutaneous Oncology
- Hospice and Palliative Care Medicine
- Health Disparity, Minority and Vulnerable Populations
- Breast Cancer
- Filipino American

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Division of Oncology (2008) CA
- Residency: Santa Clara Valley Medical Center Internal Medicine Residency (2005) CA
- Medical Education: University of Vermont College of Medicine (2002) VT
- Board Certification: Hospice and Palliative Medicine, American Board of Internal Medicine (2012)
- Fellowship, Stanford University , Medical Oncology (2008)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2008)
- Residency, Santa Clara Valley Medical , Categorical Internal Medicine (2005)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2005)
- B.A., U.C. Berkeley , Molecular and Cell Biology (1996)
- M.D., University of Vermont College , Medicine (2002)

Scientific Focus

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Gastrointestinal Malignancies, Clinical Trials

PUBLICATIONS

- **Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.** *BMC cancer*
Johnson, D. B., Atkins, M. B., Hennessy, C., Wise-Draper, T., Heilman, H., Awosika, J., Bakouny, Z., Labaki, C., Saliby, R. M., Hwang, C., Singh, S. R., Balanchivadze, N., Friese, et al
2023; 23 (1): 265
- **Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.** *JAMA oncology*
Bakouny, Z., Labaki, C., Grover, P., Awosika, J., Gulati, S., Hsu, C. Y., Alimohamed, S. I., Bashir, B., Berg, S., Bilen, M. A., Bowles, D., Castellano, C., Desai, et al
2022
- **Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.** *JAMA network open*
Hawley, J. E., Sun, T., Chism, D. D., Duma, N., Fu, J. C., Gatson, N. T., Mishra, S., Nguyen, R. H., Reid, S. A., Serrano, O. K., Singh, S. R., Venepalli, N. K., Bakouny, et al
1800; 5 (1): e2142046
- **Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Aredo, J. V., Mambetsariev, I. n., Hellyer, J. A., Amini, A. n., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., Cabebe, E. C., Naidoo, J. n., Abuali, T. n., Salgia, R. n., Loo, et al
2021
- **A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer** *INVESTIGATIONAL NEW DRUGS*
Cabebe, E. C., Fisher, G. A., Sikic, B. I.
2012; 30 (3): 1082-1087
- **Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer** *EXPERT OPINION ON INVESTIGATIONAL DRUGS*

Cabebe, E., Fisher, G. A.
2007; 16 (4): 467-476

- **Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.** *Current treatment options in oncology*

Cabebe, E., Wakelee, H.
2007; 8 (1): 15-27

- **Sunitinib: A newly approved small-molecule inhibitor of angiogenesis** *DRUGS OF TODAY*

Cabebe, E., Wakelee, H.
2006; 42 (6): 387-398

- **Intensity-modulated radiation therapy for the spine at the University of California, Irvine.** *Medical dosimetry*

Kuo, J. V., Cabebe, E., Al-Ghazi, M., Yakoob, I., Ramsinghani, N. S., Sanford, R.
2002; 27 (2): 137-145